This illustrates the importance of interpreting PD‐L1 results with caution with the implication that 20%‐60% of patients might not be eligible for immunotherapy based on testing of one tumor site, but would be eligible based on testing of a different tumor site. This evidence concerns the gene CD274 and neoplasm.